Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oral Mucosal Escalation Goal Assessment (OMEGA) Study: A Randomized Placebo-Controlled Phase 1 Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut

Trial Profile

Oral Mucosal Escalation Goal Assessment (OMEGA) Study: A Randomized Placebo-Controlled Phase 1 Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INT 301 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions
  • Acronyms OMEGA
  • Sponsors Intrommune Therapeutics

Most Recent Events

  • 19 Feb 2025 According to an Intrommune Therapeutics media release, results were published in the Annals of Allergy, Asthma & Immunology.
  • 19 Feb 2025 Results presented in the Intrommune Therapeutics Media Release.
  • 21 May 2024 According to an Intrommune Therapeutics media release, the company presented data at Citizens JMP Life Science Conference on 13th may 2024 and the BioNJ BioPartnering Conference on 14th May 2024 and the company CEO Michael Nelsonwill represent Intrommune as a panelist at the Annual Food Allergy Fund Summiton May 23rd, 2024 at 1:00pm EDT..

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top